Key result
Once-daily enoxaparin linked to ~15-point higher thrombus response vs twice-daily dosing in pediatric VTE.
Cohort (n=71)
No
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Once-daily enoxaparin (ODE), considered standard of care for venous thromboembolism (VTE) treatment in adults, has been infrequently assessed in children. To contribute available data to a limited field, we reviewed our center's experience with ODE in treating pediatric VTE compared with twice-daily enoxaparin (TDE). MATERIALS AND METHODS: A retrospective analysis of children and adolescents 18 years of age or below diagnosed with VTE and treated at our institution with ODE or TDE maintenance therapy between April 2015 and December 2020 was performed. Patient demographics, clinical and laboratory data pertaining to VTE diagnosis, and management were gathered from electronic medical records and compared between the 2 cohorts. RESULTS: Seventy-one children met the eligibility criteria. All patients were initially treated with TDE for 2 weeks before transitioning to ODE maintenance therapy (n=39; 55%) or continuing with TDE dosing (n=32; 45%).Extremity VTE was more common in ODE ( P =0.051) versus pulmonary/intracardiac sites in TDE ( P =0.002) when compared with other sites. Median enoxaparin dosing was 1.5 and 1.1 mg/kg/dose in ODE and TDE cohorts, respectively. Bleeding episodes were rare without any difference between the cohorts. Two patients (6%) were lost to follow up in TDE cohort. All evaluable patients in both cohorts had either complete/partial response (ODE n=35 [90%]; TDE n=24 [75%] or stable thrombus ODE n=4 [10%]; TDE n=6 [19%]). CONCLUSIONS: Our results indicate that ODE, used after the initial TDE treatment period, is as safe and efficacious as TDE maintenance for the treatment of pediatric VTE. The difference in VTE sites may have contributed to the equal efficacy of both the cohorts. Future prospective studies in pediatric VTE are needed to validate these results.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2022) conducted a cohort in Pediatric venous thromboembolism (n=71). Once-daily enoxaparin maintenance therapy vs. Twice-daily enoxaparin maintenance therapy (median 1.1 mg/kg/dose) was evaluated on Complete or partial thrombus response. Once-daily enoxaparin maintenance therapy achieved complete/partial thrombus response in 90% of pediatric VTE patients vs 75% with twice-daily dosing, with rare bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: